<< Nanosensor arrays ''sniff out" cancer | Nanoscopic 'pearl necklaces' track and attack cancer cells >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Hybrid metal and organic nanoparticles for targeting, imaging, and treating cancer

Published on April 27, 2009 at 4:37 PM · No Comments

Using a set of three biocompatible polymers and a nanoparticle containing gadolinium, a team of investigators at the Colorado School of Mines has created a nanoparticle platform that has the potential to target, image, and treat cancer.

Gadolinium ions are used widely in medical imaging because of their ability to dramatically boost magnetic resonance imaging (MRI) signals. However, gadolinium can be toxic, particularly to the kidneys, so researchers have examined numerous ways of creating gadolinium constructs that would shield this element from the body.

Writing in the journal Biomacromolecules, a team of investigators led by Stephen Boyes, Ph.D., solved this biocompatibility problem while creating a versatile nanoparticle, platform-attaching tumor-targeting molecules, and therapeutic agents. The investigators started by creating gadolinium nanoparticles in which the gadolinium ions were stably constrained with an organic framework. Next, they grew a three-component polymer on a nanoparticle surface using a chemical process known as reversible addition-fragmentation chain transfer (RAFT). The resulting polymer coating proved in tests to be both biocompatible and highly stable. In addition, the coating contained various chemical groups that enabled the researchers to attach the anticancer agent methotrexate and a tumor-targeting peptide known as GRGDS. The researchers note that they could have chosen other targeting and therapeutic agents to attach to the polymer coating.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading